---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-411298"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2026-10-02T12:05:48+00:00"
generated_at: "2026-10-12T14:31:46.025728+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surrozen wins FDA clearance for SZN-8141 IND; $95.1M second closing milestone triggered

## Summary
- FDA cleared Surrozen's IND for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody given as an intravitreal injection for diabetic macular edema (DME).
- First patient dosing in the Phase 1b/2a DUET study in DME expected in Q4 2026, with initial data expected in the second half of 2027.
- IND clearance satisfies the second closing milestone of the March 2025 two-tranche private placement; ~$95.1M in gross proceeds expected on or about October 20, 2026.
- Proceeds will support SZN-8141, SZN-8143 and broader operations; an S-3 resale registration must be filed within 30 days of closing.
- Surrozen also plans to develop SZN-8141 in neovascular age-related macular degeneration and is evaluating other retinal vascular diseases.

## SEC filing metadata
- accession: 0001193125-26-411298
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2026-10-02T12:05:48+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/0001193125-26-411298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/srzn-20261002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-411298
- JSON: https://secwatch.observer/filing/0001193125-26-411298.json
- Plain text: https://secwatch.observer/filing/0001193125-26-411298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.